SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bladergroen, B. A. Articles by Kummer, J. A. Search for Related Content PubMed PubMed Citation Articles by Bladergroen, B. A. Articles by Kummer, J. A. Related Collections Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 January 2002, Vol. 99, No. 1, pp. 232-237 NEOPLASIA Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Bellinda A. Bladergroen, Chris J. L. M. Meijer, Rosita L. ten Berge, C. Erik Hack, Jettie J. F. Muris, Danny F. Dukers, Andreas Chott, Yoshiaki Kazama, Joost J. Oudejans, Oskar van Berkum, and J. Alain Kummer From the Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands; Department of Pathophysiology of Plasma Proteins, CLB, Amsterdam, The Netherlands; Department of Clinical Pathology, General Hospital Vienna, Austria; and Department of Pathology, University of New Mexico, Albuquerque. In tumor cells, the serine protease granzyme B is the primary mediator of apoptosis induced by cytotoxic T lymphocytes (CTLs)/natural killer (NK) cells. The human intracellular serpin proteinase inhibitor 9 (PI9) is the only known human protein able to inhibit the proteolytic activity of granzyme B. When present in the cytoplasm of T lymphocytes, PI9 is thought to protect CTLs against apoptosis induced by their own misdirected granzyme B. Based on the speculation that tumors may also express PI9 to escape CTL/NK cell surveillance, immunohistochemical studies on the expression of PI9 in various lymphomas were performed. Ninety-two cases of T-cell non-Hodgkin lymphoma (NHL), 75 cases of B-cell NHL, and 57 cases of Hodgkin lymphomas were stained with a PI9-specific monoclonal antibody. In T-cell NHL, highest PI9 expression was found in the extranodal T-cell NHL. In nearly 90% of enteropathy-type T-cell NHLs and 80% of NK/T-cell, nasal-type lymphomas, the majority of the tumor cells expressed PI9. In nodal T-anaplastic large cell lymphomas and peripheral T-cell lymphomas (not otherwise specified), PI9 expression occurred less frequently. In B-cell NHL, PI9 expression was associated with high-grade malignancy; 43% of diffuse large B-cell lymphomas showed PI9+ tumor cells. Finally, PI9 expression was also found in 10% of Hodgkin lymphomas. This is the first report describing the expression of the granzyme B inhibitor PI9 in human neoplastic cells in vivo. Expression of this inhibitor is yet another mechanism used by tumor cells to escape their elimination by cytotoxic lymphocytes. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Getachew, H. Stout-Delgado, B. C. Miller, and D. L. Thiele Granzyme C Supports Efficient CTL-Mediated Killing Late in Primary Alloimmune Responses J. Immunol., December 1, 2008; 181(11): 7810 - 7817. [Abstract] [Full Text] [PDF] M. Bots and J. P. Medema Serpins in T cell immunity J. Leukoc. Biol., November 1, 2008; 84(5): 1238 - 1247. [Abstract] [Full Text] [PDF] C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF] A. S.K. de Hooge, D. Berghuis, S. J. Santos, E. Mooiman, S. Romeo, J. A. Kummer, R. M. Egeler, M. J.D. van Tol, C. J.M. Melief, P. C.W. Hogendoorn, et al. Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways Clin. Cancer Res., January 1, 2007; 13(1): 206 - 214. [Abstract] [Full Text] [PDF] Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma. Cancer Res., October 15, 2006; 66(20): 10145 - 10152. [Abstract] [Full Text] [PDF] R. Godal, U. Keilholz, L. Uharek, A. Letsch, A. M. Asemissen, A. Busse, I.-K. Na, E. Thiel, and C. Scheibenbogen Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 Blood, April 15, 2006; 107(8): 3205 - 3211. [Abstract] [Full Text] [PDF] C. J. Winrow, D. G. Pankratz, C. R. T. Vibat, T.J. Bowen, M. A. Callahan, A. J. Warren, B. S. Hilbush, A. Wynshaw-Boris, K. W. Hasel, Z. Weaver, et al. Aberrant recombination involving the granzyme locus occurs in Atm-/- T-cell lymphomas Hum. Mol. Genet., September 15, 2005; 14(18): 2671 - 2684. [Abstract] [Full Text] [PDF] I. S. van Houdt, J. J. Oudejans, A. J.M. van den Eertwegh, A. Baars, W. Vos, B. A. Bladergroen, D. Rimoldi, J. J.F. Muris, E. Hooijberg, C. M. Gundy, et al. Expression of the Apoptosis Inhibitor Protease Inhibitor 9 Predicts Clinical Outcome in Vaccinated Patients with Stage III and IV Melanoma Clin. Cancer Res., September 1, 2005; 11(17): 6400 - 6407. [Abstract] [Full Text] [PDF] T. Alvaro, M. Lejeune, M. T. Salvado, R. Bosch, J. F. Garcia, J. Jaen, A. H. Banham, G. Roncador, C. Montalban, and M. A. Piris Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells Clin. Cancer Res., February 15, 2005; 11(4): 1467 - 1473. [Abstract] [Full Text] [PDF] M. Bots, I. G. M. Kolfschoten, S. A. Bres, M. T. G. A. Rademaker, G. M. de Roo, M. Kruse, K. L. M. C. Franken, M. Hahne, C. J. Froelich, C. J. M. Melief, et al. SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity Blood, February 1, 2005; 105(3): 1153 - 1161. [Abstract] [Full Text] [PDF] S. Poppema Immunobiology and Pathophysiology of Hodgkin Lymphomas Hematology, January 1, 2005; 2005(1): 231 - 238. [Abstract] [Full Text] [PDF] M. B. Barrie, H. W. Stout, M. S. Abougergi, B. C. Miller, and D. L. Thiele Antiviral Cytokines Induce Hepatic Expression of the Granzyme B Inhibitors, Proteinase Inhibitor 9 and Serine Proteinase Inhibitor 6 J. Immunol., May 15, 2004; 172(10): 6453 - 6459. [Abstract] [Full Text] [PDF] J J Oudejans, R L ten Berge, and C J L M Meijer Immune escape mechanisms in ALCL J. Clin. Pathol., June 1, 2003; 56(6): 423 - 425. [Full Text] [PDF] H. Johnson, L. Scorrano, S. J. Korsmeyer, and T. J. Ley Cell death induced by granzyme C Blood, April 15, 2003; 101(8): 3093 - 3101. [Abstract] [Full Text] [PDF] R. K. Batra, Y. Lin, S. Sharma, M. Dohadwala, J. Luo, M. Pold, and S. M. Dubinett Non-Small Cell Lung Cancer-derived Soluble Mediators Enhance Apoptosis in Activated T Lymphocytes through an I{kappa}B Kinase-dependent Mechanism Cancer Res., February 1, 2003; 63(3): 642 - 646. [Abstract] [Full Text] [PDF] C. E. Hirst, M. S. Buzza, C. H. Bird, H. S. Warren, P. U. Cameron, M. Zhang, P. G. Ashton-Rickardt, and P. I. Bird The Intracellular Granzyme B Inhibitor, Proteinase Inhibitor 9, Is Up-Regulated During Accessory Cell Maturation and Effector Cell Degranulation, and Its Overexpression Enhances CTL Potency J. Immunol., January 15, 2003; 170(2): 805 - 815. [Abstract] [Full Text] [PDF] D. Vermijlen, D. Luo, C. J Froelich, J. P. Medema, J. A. Kummer, E. Willems, F. Braet, and E. Wisse Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway J. Leukoc. Biol., October 1, 2002; 72(4): 668 - 676. [Abstract] [Full Text] [PDF] F. H. Igney and P. H. Krammer Immune escape of tumors: apoptosis resistance and tumor counterattack J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920. [Abstract] [Full Text] [PDF] R. L. ten Berge, C. J. L. M. Meijer, D. F. Dukers, J. A. Kummer, B. A. Bladergroen, W. Vos, C. E. Hack, G. J. Ossenkoppele, and J. J. Oudejans Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma Blood, May 29, 2002; 99(12): 4540 - 4546. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020